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MaOBJECTIVES This study sought to evaluate acute and long-term outcomes of percutaneous paravalvular regurgitation
(PVR) closure after transcatheter aortic valve replacement (TAVR).
BACKGROUND Severe symptomatic PVR is a predictor of all-cause mortality after TAVR. The current use of
devices for transcatheter closure of PVR has been adapted from other indications without known long-term
outcomes.
METHODS The study population consisted of a series of cases pooled together from an international multicenter
experience. Patients underwent transcatheter implantation of a closure device for the treatment of clinically relevant
PVR after TAVR with balloon-expandable or self-expandable prostheses. Procedural success was deﬁned by
successful deployment of a device with immediate reduction of PVR to a ﬁnal grade #2 as assessed by
echocardiography.
RESULTS Twenty-seven procedures were performed in 24 patients with clinically relevant PVR after the index TAVR
procedure (54.2% Edwards Sapien [Edwards Lifesciences, Irvine, California], 45.8% CoreValve [Medtronic, Minneapolis,
Minnesota]). The study population included 75% men with a mean age of 80.6  7.1 years and mean Society of Thoracic
Surgeon score of 6.6%. The most frequently used device was Amplatzer Vascular Plug (St. Jude Medical, St. Paul,
Minnesota) in 80% of the cases. Overall, 88.9% (24 of 27) of the procedures were technically successful and the results
assessed by echocardiography were durable. However, cumulative survival rates at 1, 6, and 12 months were 83.3%,
66.7%, and 61.5%. Most of the deaths (8 of 11) were due to noncardiac causes.
CONCLUSIONS Transcatheter closure of PVR after TAVR can be performed with a high procedural success rate;
however, the long-term mortality remains high mainly due to noncardiac causes. (J Am Coll Cardiol Intv 2015;8:681–8)
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ABBR EV I A T I ON S
AND ACRONYMS
AR = aortic regurgitation
AVR = aortic valve
replacement
PVR = paravalvular
regurgitation
TAVR = transcatheter aortic
valve replacement
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682T ranscatheter aortic valve replace-ment (TAVR) is an effective treat-ment for patients with severe
symptomatic aortic stenosis who are consid-
ered either ineligible or at high risk for surgi-
cal AVR (1,2). After conventional AVR, the
occurrence of paravalvular regurgitation
(PVR) is infrequent and often necessitates
rapid action (3,4). Conversely, residual PVR
is more common after TAVR and has been re-ported in up to 90% of the patients independent of
either of the 2 available types of devices and ap-
proaches (5). In most cases, PVR is mild and clinically
silent. However, when moderate or severe it has been
associated with hemodynamic deterioration and
worse early (6) and late (7) clinical outcome.SEE PAGE 689When aortic regurgitation (AR) is exclusively or
mainly paravalvular, the possible mechanisms are as
follow: 1) malposition (too high or too low with
respect to the aortic annulus); 2) annulus/prosthesis
mismatch; 3) incomplete expansion of the prosthesis
stent frame; and 4) presence of bulky calciﬁed nod-
ules preventing the good adherence of the bio-
prosthesis to the left ventricular outﬂow tract. Based
on the pathophysiology, the management strategy
includes post-dilation (8), valve-in-valve implanta-
tion (9), or repositioning with the snare technique
(10). Sometimes, however, none of these techniques
are effective, necessitating additional maneuvers.
Transcatheter closure of PVR has been previously
described for post-surgical valves (11,12). More
recently, percutaneous device closure of PVR
following TAVR have been described in small series,
with single center experience and have focused on a
particular valve type (13–17). In addition, the devices
used for transcatheter closure of PVR defects are
adapted from other indications and long-term out-
comes are unknown. The current study was aimed to
represent the largest multicenter case series of pa-
tients who underwent transcatheter closure of PVR
after Edwards prostheses (Edwards Sapien and Sapien
XT, Edwards Lifesciences, Irvine, California) or
Medtronic CoreValve (Minneapolis, Minnesota) with
long-term follow-up.
METHODS
POPULATION AND PROCEDURE. We examined the
clinical, procedural, and long-term follow-up data of
all consecutive patients with clinically relevant PVR
after TAVR who underwent percutaneous closure of a
paravalvular defect at 4 high-volume catheterizationlaboratories in different countries: the United States,
Italy, Germany, and Canada. There was no restriction
for the type of TAVR previously implanted in the aortic
position, namely the self-expanding Medtronic Core-
Valve or 1 of the balloon-expandable Edwards pros-
theses (Edwards Sapien and Sapien XT). Decision to
perform the PVR closure was clinically driven in all
cases. To date, there are no devices that have been
developed and labeled for this purpose, hence selec-
tion of the device for PVR closure and othermaterial for
the procedure, vascular access, use of additional dia-
gnostic tools, and periprocedural and post-procedural
medications were at the operators’ discretion.
DEFINITIONS AND OBJECTIVES. The surgical risk
before TAVR was estimated with the STS-PROM
(Society of Thoracic Surgery Predicted Risk of Mor-
tality) (18) and the logistic EuroSCORE (European
System for Cardiac Operative Risk Evaluation) (19).
In addition, patients were classiﬁed as inoperable or
at high risk for surgery based on the judgment by the
heart team. Symptomatic status before and after PVR
closure was classiﬁed based on the New York Heart
Association functional class. Prosthetic PVR was
classiﬁed by echocardiography using recommended
semiquantitative criteria (20,21): 0 ¼ absent, no
regurgitant color ﬂow; 1 ¼ trace, pinpoint jet; 2 ¼
mild-to-moderate, circumferential extension <10%;
3 ¼ moderate-to-severe, circumferential extension
10% to 29%; and 4 ¼ severe, circumferential extension
$30% and/or holodiastolic ﬂow reversal in the
descending aorta. Because PVR may be caused by
different and often multiple mechanisms (5,13,22), in
this study, physicians were asked to retrospectively
classify the main mechanism into 4 categories based
on all available imaging documentation: high im-
plant (part of the inﬂow aspect of the prosthesis lies
above the annular ring, allowing a regurgitation
from the aortic sinus below the tissue skirt into the
left ventricle); low implant (implantation of the
prosthesis or part of the sealing pericardial skirt of
the prosthesis below the virtual annular ring, leaving
an open communication between the aorta and the
left ventricle); undersized valve (mismatch between
the annulus size and the prosthesis); and incomplete
adherence to the annulus (correct device sizing but
presence of bulky native valve calciﬁcations causing
incomplete apposition of the frame). Procedural
success was deﬁned by successful deployment of a
closure device with immediate reduction in the de-
gree of PVR with a ﬁnal grade #2 as assessed by
echocardiography. The occurrence of adverse events
was evaluated using recommended criteria (20).
Myocardial infarction was attributed by a combina-
tion of clinical criteria and cardiac biomarkers
TABLE 1 Baseline Characteristics (N ¼ 24)
Demographics
Age, yrs 80.6  7.1
Male 18 (75.0)
Clinical history
Diabetes 10 (41.7)
Hypertension 22 (91.7)
Previous myocardial infarction 8 (33.3)
Previous coronary artery bypass graft 4 (16.7)
Previous cardiac surgery 4 (16.7)
Previous cerebrovascular accident 5 (20.8)
Chronic obstructive pulmonary disease 5 (20.8)
Surgical risk
STS score, % 6.6  3.9
Logistic EuroSCORE, % 23.5  20.1
Porcelain aorta 7 (29.2)
Inoperable 21 (87.5)
High-risk 3 (12.5)
TAVR device
Medtronic CoreValve 11 (45.8)
Edwards Sapien 13 (54.2)
Access route for TAVR
Transfemoral 18 (75.0)
Transapical 5 (20.8)
Subclavian 1 (4.2)
Clinical presentation
NYHA II 2 (8.3)
NYHA III 16 (66.7)
NYHA IV 6 (25.0)
Echocardiography
AR grade after TAVR
Grade 2 1 (4.2)
Grade 3 10 (41.7)
Grade 4 13 (54.2)
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683(universal deﬁnition of myocardial infarction > 72 h
after the index procedure; within 72 h from the
procedure threshold values were >15 the upper
reference limit for troponin or 5 for creatine ki-
nase–myocardial band). Cerebrovascular accidents
included transient ischemic attack and stroke.
Serious bleeding was deﬁned as the need of trans-
fusion or intervention. Acute kidney injury was
classiﬁed as stage 1 (increase in serum creatinine to
150% to 199% compared with baseline or increase of
>0.3 mg/dl), stage 2 (increase in serum creatinine to
200% to 299%), or stage 3 (increase in serum creat-
inine to $300% or serum creatinine of >4.0 mg/dl
with an acute increase of at least 0.5 mg/dl). Clini-
cians were asked to report any serious vascular
complication, including any aortic damage or access-
related vascular injury leading to a serious bleeding
or requiring intervention. Participating investigators
were asked to provide the longest available follow-
up and the most updated echocardiography data.
All patients provided written informed consent
before the procedure and also gave written informed
consent for the processing of their anonymous data.
STATISTICAL ANALYSIS. Continuous variables were
expressed as mean  SD. Categorical variables were
presented as frequencies and percentages. Survival
during follow-up was estimated with the Kaplan-
Maier curve. All analyses were performed with the
SPSS software (version 17.0, SPSS Inc., Chicago,
Illinois).LVEF before PVR closure 54  13
Post-dilation after TAVR 18 (75.0)
Valve-in-valve after TAVR 1 (4.2)
Values are mean  SD or n (%).
AR ¼ aortic regurgitation; EuroSCORE¼ European System for Cardiac Operative
Risk Evaluation; LVEF ¼ left ventricle ejection fraction; NYHA ¼ New York Heart
Association; PVR ¼ paravalvular regurgitation; STS ¼ Society of Thoracic Surgery;
TAVR ¼ transcatheter aortic valve replacement.RESULTS
Overall, 27 procedures were performed in 24 patients
(1 patient underwent 3 and another patient had 2
procedures). None of the patients had central AR
grade $2. The procedures were performed 316  515
days (range 3 to 1,409) after TAVR. Baseline patients’
characteristics are listed in Table 1. The study popu-
lation included 75% men and 25% women with a
mean age of 80.6  7.1 years and mean Society of
Thoracic Surgeon Score of 5.4  3.9%. Seven patients
(29.2%) had porcelain aorta. In total, 13 patients
(54.2%) had an Edwards Sapien valve, and 11 (45.8%)
a Medtronic CoreValve. The vast majority of the pa-
tients were in New York Heart Association functional
class III/IV (91.7%). Valve post-dilation after TAVR
was attempted in 18 patients (75.0%), either at the
time of index procedure (15 of 18) or just before the
PVR closure procedure (3 of 18), and 1 patient had
undergone valve-in-valve procedure (4.2%) at the
time of the index procedure. Figure 1 describes the
main estimated cause of PVR. Table 2 summarizesthe procedural details. The procedures were per-
formed under general anesthesia in 13 of 27 patients
(48.2%), deep sedation in 7 (25.9%), and local anes-
thesia in 7 (25.9%). Transesophageal echocardi-
ography was used in 20 procedures (74.1%) and
intracardiac echocardiography in 1. Overall, 22 pro-
cedures (81.5%) were performed with retrograde
approach from the aorta and 5 (18.5%) via antegrade
transseptal approach. Different catheters (4- to 6-F)
were used to cross the leak, and various devices (6 to
15 mm) were deployed (Table 2). Considering the
single procedures, transcatheter PVR closure was
successful in 24 of 27 cases (88.9%); ﬁnal success
(including multiple procedures in 2 patients) was
FIGURE 1 Causes of PVR
Main mechanism of paravalvular regurgitation (PVR) estimated on the basis of available
imaging.
TABLE 2 Procedural
ID #
Annulus
Size (TTE)
(mm) TAV
1 23 Cor
2 20 Cor
3 26 Cor
4 22 Sap
5 26 Cor
6 24 Sap
7 22 Sap
8 21 Sap
9* 23 Sap
10* 23 Sap
11* 23 Sap
12 21 Sap
13 21 Sap
14 23 Sap
15* 21 Sap
16* 21 Sap
17 23 Sap
18 24 Sap
19 22 Cor
20 18.5 Cor
21 24 Cor
22 19.5 Cor
23 29.5 Cor
24 26 Sap
25 29 Cor
26 20 Sap
27 24 Sap
*Multiple procedures in th
AL ¼ Amplatz left; AVP
SCL ¼ subclavian; TA ¼ tra
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684achieved in 22 of 24 patients (91.7%). In 1 procedure,
the attempt to cross the leak with the wire was un-
successful; in another case, the transcatheter valve
was displaced supra-annularly during the attemptCharacteristics of Transcatheter Closure of PVR
R Type
Valve Size
(mm)/Route Location of PVR
Mechanism
of PVR
Balloon
Post-Dilation
eValve 26/TF Anterior Low implant Yes
eValve 29/SCL Anterior Low implant No
eValve 29/TF Anterior/posterior IAA Yes
ien 23/TF Posterior IAA Yes
eValve 29/TF Anterior Low implant No
ien 26/TA Anterior Undersized Yes
ien 23/TA Anterior Undersized Yes
ien 26/TA Anterior/posterior Low implant No
ien 26/TA Anterior/posterior Low implant Yes
ien 26/TA Posterior — —
ien 26/TA Posterior — —
ien 23/TA Anterior/posterior IAA Yes
ien 26/TF Anterior/posterior IAA Yes
ien 26/TF Concentric and central IAA Yes
ien 26/TF Posterior/anterior High implant Yes
ien 26/TA Posterior — —
ien 26/TF Posterior High implant No
ien 26/TF Anterior/posterior IAA Yes
eValve 29/TF Posterior/ Low implant No
eValve 26/TF Anterior IAA Yes
eValve 29/TF Anterior/posterior IAA Yes
eValve 27/TF Anterior/posterior IAA Yes
eValve 31/TF Anterior IAA Yes
ien 26/TF Posterior IAA No
eValve 29/TF Posterior IAA Yes
ien XT 20/TF Posterior Undersized Yes
ien XT 26/TF Posterior Undersized Yes
e same patient.
¼ Amplatzer Vascular Plug; F ¼ French; IAA ¼ incomplete adherence to the annulus; JR
nsapical; TF ¼ transfemoral; TTE ¼ transthoracic echocardiography; VSD ¼ Ventricular Septo cross the leak. The embolized valve was immedi-
ately repositioned using an inﬂated balloon in the
descending aorta and a second larger valve was then
successfully implanted in the correct position. A
third patient had a residual PVR grade 3 (baseline
grade 4). Devices used were as follow: Amplatzer
Vascular Plug 2, 3, or 4 (St. Jude Medical, St. Paul,
Minnesota) in 20 procedures (80%); Ventricular
Septal Defect occluder (St. Jude Medical) in 4 (16%);
and the Azur HydroCoil (Terumo Corporation, Tokyo,
Japan) was attempted in 1 where it was not suc-
cessful. In 6 cases (22.2%), 2 devices were necessary
to obtain a good procedural result. Average proce-
dural duration was 86  62 min, with a total amount
of contrast dye of 89  74 cc (range 0 to 300 cc; 4
cases were accomplished without contrast and 11
with <50 cc). There were 8 serious periprocedural
complications (29.7%): 1 minor stroke without residual
deﬁcit (24 h after the procedure, in a patient with
recurrent cerebrovascular accidents and severe not
treatable bilateral carotid stenosis); 1 serious bleedingDays After
TAVR
Closure
Device
Guiding
Catheter
Device Size(s)
(mm)
803 AVP 2 AL1 6-F 8
685 AVP 4 AL1 6-F 6/8
740 AVP 4 MP 5-F 8
742 AVP 4 MP 6-F 8
715 AVP 2 MP 6-F 8
37 AVP 2 MP 6-F 6/8
1,409 AVP 2 MP 5-F 8/10
30 AVP 2 AL2 6-F 6
55 AVP 2 AL2 6-F 12
86 Azur Terumo Coil AL2 6-F 15
177 VSD AL1 6-F 8
3 VSD AL2 6-F 10
43 AVP 2 AL2 4-F 12
253 VSD AL1 6-F 10
142 AVP 2 AL2 6-F 12
177 N/A N/A N/A
17 VSD AL3 6-F 8
607 AVP 2 AL2 6-F 6
869 AVP 4 AL1 5-F 5
98 AVP 3 AL1 5-F 3
10 AVP 4 AL1 5-F, JR4 5-F 4/5
27 AVP 3 JR4 5-F 5
21 AVP 2, AVP 3 MP 5-F/ AL1 5-F 4/5
758 AVP 3 JR4 5-F 5
36 AVP 4 MP 6-F 12
54 N/A N/A N/A
74 AVP 2 Destiny Terumo 7-F 8/10
¼ Judkins right; MP ¼ multipurpose; N/A ¼ not available (unsuccessful procedure);
tal Defect Occluder; — ¼ same patient as above; other abbreviations as in Table 1.
FIGURE 2 Changes in AR and Functional Status After the Procedure
(A) Aortic regurgitation (AR) assessed with echocardiography before paravalvular regur-
gitation (PVR) closure, after the procedure, and during follow-up. For a reliable compar-
ison of post-procedural and follow-up results, only paired data for patients with at least 1
evaluation >30 days (*) were included (18 patients, average timing of echocardiography
8.8  7.7 months, range 1 to 27 months. Exclusions: 3 deaths in <30 days, 1 patient with
valve-in-valve procedure, 2 patients without echocardiography at >30 days). (B) New York
Heart Association (NYHA) functional class before and after PVR closure procedure in the 24
patients. For patients with multiple procedures, functional status was assessed after the
last procedure.
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685(3.7%) (pulmonary hemorrhage); 3 cases of acute kid-
ney injury stage 3 (11.1%); 2 cases of ventilator-
associated pneumonia; and 1 valve embolization. No
serious vascular complications were observed. The
acute and mid-term procedural results evaluated with
echocardiography are shown in Figure 2A. Before the
procedure, 13 patients had grade 4 AR, 13 had grade 3,
and 1 patient had grade 2 AR. After the procedure there
were no patients with AR grade 4, 2 (7.4%) with AR
grade 3, 9 (33.3%) with grade 2, and 16 with grades
0 and 1 (59.3%). Remarkably, the 2 patients with AR
grade 3 after the procedure showed an AR grade 2
during follow-up. Functional status changes between
PVR closure and the time of the last follow-up are
described in Figure 2B. During an average follow-up of
12.3  11.4 months (range 0 to 31 months), 11 patients
expired: 3 were deaths of cardiovascular origin
(2 worsening heart failure, 1 endocarditis); and 8 were
from noncardiovascular causes. Among deaths of
noncardiovascular origin, 3 were procedure-related
(1 acute renal failure, 2 ventilator-associated pneu-
monia and respiratory failure) and 5 were not
procedure-related (1 late acute renal failure, 1 cancer, 1
clostridium difﬁcile infection, 2 progressive senes-
cence). Of importance, post-procedure AR grade
was #2 in all patients who died, including those who
died because of worsening heart failure. Cumulative
survival at 1, 6, and 12 months was 83.3%, 66.7%, and
61.5% (Figure 3), respectively. At 2-year follow-up,
cumulative survival was 55.4%.
DISCUSSION
We describe the long-term outcome of percutaneous
closure of clinically relevant paravalvular aortic
regurgitation after TAVR. The principal ﬁndings of
our study can be summarized as follows: 1) percu-
taneous closure of PVR after TAVR is a complex, not
standardized procedure, which carries sizable risks;
2) the procedure can be accomplished with high
success rates and is associated with an improved
functional status in many patients, but the overall
clinical efﬁcacy remains to be demonstrated. There
was a high rate of serious periprocedural complica-
tions and high mortality during follow-up; and 3) the
reduction of AR seems stable or even reduced during
follow-up.
Several cases of successful use of various occluder
devices have been described for transcatheter closure
of PVR post-TAVR. In previous reports, we described
both antegrade and retrograde transcatheter PVR
closure with different devices and using different
guiding catheters (13–15). We highlighted a number of
potential drawbacks, including the difﬁculty crossingthe PVR space with the wire, the failure to advance
the guiding catheters through the struts of the valve
on the aortic side, the need to shift approaches, and
the risk of device embolization (14). The present study
conﬁrms that percutaneous closure of PVR is a com-
plex and customized procedure. Different patient
management strategies were used in this series
including type of anesthesia, guiding catheters to
cross the leak, and closure devices. The preferred
devices were the Amplatzer Vascular Plugs, which are
a family of braided-nitinol self-expanding devices
FIGURE 3 12-Month Survival After the Procedure
Kaplan-Meier cumulative survival after paravalvular regurgitation closure.
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686designed for transcatheter vessel embolization. Of
interest, in 7 of 27 cases (26%), the procedure was
performed under local anesthesia without echocardi-
ography guidance. Multiple closure devices were used
less frequently in comparison to post-surgical PVR
closure series (23). This may be due to the smaller
extent of leakage in transcatheter prostheses or to the
more limited space available in between the pros-
thetic valve frame and native structures.
The rate of periprocedural complications was sig-
niﬁcant (29.7%), and acute kidney injury was the most
frequent complication. This observation discourages
the use of contrast dye during the procedure in this
fragile cohort of patients. Indeed, in 4 cases, no
contrast was used, suggesting the feasibility of this
strategy. In 1 case, there was displacement of the
previously implanted transcatheter valve, which was
successfullymanaged by repositioning the valve in the
descending aorta and implanting a second larger valve
in the annulus. It is important to note the challenge of
passing a delivery sheath through highly irregular
spaces that may lead to valve dislodgement. The
ability to use smaller diagnostic catheters to deliver
occluder devices across PVR may certainly reduce this
risk. The low proﬁle Amplatzer Vascular Plug 4 is
compatible with 0.038-inch diagnostic catheters and
recently Feldman et al. (17) described 6 cases of suc-
cessful transcatheter PVR closure after using EdwardsSapien prosthesis with 4- to 5-F catheters. There were
2 cases that suffered from ventilator-associated
pneumonia that led to respiratory failure and death.
Hence, avoiding general anesthesia and use of a
retrograde approach should be strongly considered
especially in severely compromised patients.
In terms of efﬁcacy, PVR grade was signiﬁcantly
reduced in most of the patients (Figure 2), and
these results seemed durable. The mortality rate at
follow-up was high, but in most of the cases, deaths
were due to noncardiac causes and related to the se-
vere comorbidities. The high rate of mortality, how-
ever, may still raise concerns. We did not have a
reliable control population, so it is difﬁcult to esti-
mate the true impact of our procedures on the ﬁnal
outcome. Previous studies reported 1-year mortality
rates between 30% and 70% in patients with
moderate-to-severe AR after TAVR (24–29). Consid-
ering available data and the fact that 87.5% of our
patients were deemed inoperable, in many instances
because of comorbidity other than that captured by
surgical scores, the fatality rate of our series seems
more justiﬁable.
Signiﬁcant PVR may be detected and treated both
during the TAVR procedure or later on, as was done in
the cases reported herein. Different treatment stra-
tegies may be preferred based on the timing of
detection and the cause of PVR. In our series, the
most common (50%) cause of PVR after TAVR was
incomplete adherence of the inﬂow aspect of the
prosthesis to the aortic annulus. Severe native valve
calciﬁcations may cause incomplete/asymmetrical
expansion of the frame, and bulky calciﬁcations may
interfere with the adherence of the prosthesis to the
annulus. In such cases, post-dilation appears to be
very effective in reducing the degree of AR (8).
Excessive post-dilation should however, be avoided
to prevent leaﬂets damage and consequent severe
central regurgitation. Another risk of post-dilation is
annular rupture that, although infrequent, may be
fatal. When post-dilation is not effective and there is
a residual focal PVR, the use of a closure device may
be considered.
The second most frequent (25%) mechanism of
PVR in our study was low implantation of the pros-
thesis or part of the prosthesis. In such cases, a part
of the sealing pericardial skirt of the prosthesis is
located below the virtual annular ring of the annulus,
leaving an open communication between the aorta
and the left ventricle (13). In these cases, post-
dilation is generally not useful. Minimal reposition-
ing by pulling the valve with the snare technique
is possible but is often ineffective and poten-
tially dangerous (10). A possible solution is the
PERSPECTIVES
PVR is common after TAVR and is associated with a worse clinical
outcome. Management of clinically relevant PVR is challenging:
although anecdotal cases of percutaneous treatment with
closure devices adapted from other indications have been re-
ported, the procedure is not standardized and information about
mid-term outcomes is lacking.
This multicenter study reports a series of cases of percutaneous
PVR closure after TAVR, providing procedural details, echocar-
diographic results, and mid-term clinical outcome. This thera-
peutic option may be useful in selected patients, but further
investigation and development of dedicated devices would be
desirable.
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687implantation of a second valve within the ﬁrst one:
the valve-in-valve technique (9). This procedure is
very effective, has a favorable procedural outcome,
and should probably be preferred when severe AR is
manifest at the end of TAVR procedure. Our study
suggests that transcatheter PVR closure may be
considered as an alternative to a second TAVR pro-
cedure when valve-in-valve is not performed during
the ﬁrst procedure, as long as there is a focal area
where a device can be of use. High implantation of
the prosthetic valve was a less frequent event in our
series, maybe because it is less amenable to trans-
catheter treatment described herein. Post-dilation
maybe helpful in these cases; however, valve-in-
valve is the best treatment, especially for high
implants with risk of embolization. The second
prosthesis should preferably be a balloon-expandable
valve, because it is required to be implanted in a
lower position, whereas with the self-expandable
prosthesis, the outﬂow tract may remain under-
expanded into the ﬁrst prosthesis.
Another relevant mechanism of PVR after TAVR is
annulus/prosthesis mismatch, that is, implantation of
an undersized prosthesis in relation to the aortic
annulus (30). Preventing incongruence between the
aortic annulus and the device is of paramount
importance; hence, multimodality assessment of the
aortic annulus size is recommended before TAVR.
Previous studies provided the evidence for a more
reliable measurement of aortic annulus and less PVR
by using 3-dimensional cross-section computed to-
mography–scan assessment (31). Post-dilation may
be attempted in these cases, and only if there is a
focal residual PVR should a closure device could be
considered.
STUDY LIMITATIONS. This is a small, retrospective
study and the use of closure devices for treatment of
PVR was off-label, driven by the clinical necessity.
The lack of a comparison group makes it difﬁcult to
estimate the beneﬁt of the procedure beyond the
impact on AR severity and reported changes in func-
tional status. Larger experience will be needed to
conﬁrm safety and efﬁcacy of this procedure. New
sizing strategies, which include multimodality imag-
ing of the aortic annulus and computed tomography
measurement of annular diameters, perimeter, andarea will likely help decrease the incidence of severe
PVR. Next-generation valves have been designed to
address the limitations of the ﬁrst-generation de-
vices, including features to reduce PVR such as seal-
ing skirts or cuffs and the ability to reposition. This
may change the incidence, the need, and the tech-
nique to close PVR (32,33).
CONCLUSIONS
The present study illustrates the potential role of
transcatheter PVR closure after TAVR with place-
ment of occluder devices and reports the long-term
outcome of this procedure. Although the procedural
success rate was high, procedural complications were
common. Long-term outcome was strongly inﬂu-
enced by noncardiac mortality, making the inter-
pretation of clinical efﬁcacy more difﬁcult. Overall,
our data suggest that percutaneous PVR closure
can be adopted in selected patients and performed
by expert operators with acceptable long-term
outcomes.
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